Please assess the completion status of the following clinical trial:

Trial Title: Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Chronic HBV infection, defined as positive serum HBsAg for at least 6 months~* 18 through 75 years of age, inclusive~* HBV DNA ≥ 10\^3 IU/mL~* Receiving treatment with lamivudine with confirmation of HBV reverse transcriptase mutation(s) known to confer resistance to lamivudine (rtM204I/V with or without rtL180M) by central laboratory assessment prior to randomization; adefovir dipivoxil treatment of ≤ 48 weeks at the time of screening (inclusive of combination adefovir dipivoxil + lamivudine at entry) was allowed~* Willing and able to provide written informed consent~* Negative serum pregnancy test (for females of childbearing potential only)~* Calculated creatinine clearance ≥ 50 mL/min~* Hemoglobin ≥ 10 g/dL~* Neutrophils ≥ 1000 /mm\^3~* No prior oral HBV therapy with approved nucleotide and/or nucleoside therapy or other investigational agents for HBV infection other than lamivudine or adefovir dipivoxil~Exclusion Criteria~* Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study~* Males and females of reproductive potential who are not willing to use an effective method of contraception during the study~* Alanine aminotransferase (ALT) ≥ 10 × the upper limit of the normal range (ULN)~* Decompensated liver disease~* Interferon or pegylated interferon therapy within 6 months of the screening visit~* Alpha fetoprotein \> 50 ng/mL~* Evidence of hepatocellular carcinoma~* Coinfection with hepatitis C virus, HIV, or hepatitis D virus~* Significant renal, cardiovascular, pulmonary, or neurological disease~* Received solid organ or bone marrow transplantation~* Receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion~* Proximal tubulopathy~* Known hypersensitivity to the study drugs, the metabolites or formulation excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tenofovir DF (Type: EXPERIMENTAL): TDF plus placebo to match FTC/TDF
- FTC/TDF (Type: EXPERIMENTAL): FTC/TDF plus placebo to match TDF

Based on this trial design, predict the completion outcome and termination type (if applicable).